HRT Hormone Replacement Therapy

HRT Hormone Replacement Therapy

 

Is there a place for progesterone replacement?

Home
Blog - What's New?
Abortion
Acne
Amenorrhoea - Absent Periods
Anatomy Female
Birth Control
Bladder Symptoms
Breast Feeding
Cancer in Women
Childbirth
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometrial Ablation
Endometriosis
Female Sexual Problems
Female Sterilization
Fibroids
Urinary Tract Infection - UTI
HRT/HormoneReplacementTherapy
Hysterectomy
Infection
Infertility
Irritable Bowel Syndrome IBS
Libido - Sex Drive
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Menstruation Menstrual Cycle
Miscarriage
Obesity
Ovarian Cysts
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Inflammatory Disease
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Prolapse
SHOP / SHOPPING MALL UK
SHOP / Shopping Mall - USA
Ultrasound
Urinary Tract Infection - UTI
Urinary Incontinence
Vaginal Discharge
Viagra, Libido and Sex Drive.
Weight Loss-Dieting
Illustrations
The Author
Contact Us

Authors:

Carey BJ. Carey AH. Patel S. Carter G. Studd JWW.

Institution:

J.W.W. Studd, Department Obstetrics Gynaecology, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH; United Kingdom.

Title:

A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women (2000-3123).

Source:

British Journal of Obstetrics and Gynaecology. Vol 107(6) (pp22-726), 2000.

Abstract:

Objective. To determine the pharmacokinetics of a progesterone cream following short and long term dermal administration. Design. Single-centre, randomised, multiple-dose, open-label study. Setting. Reproductive Medicine Trust, London. Population. Twenty-four healthy postmenopausal women aged between 40 and 65 years were recruited through an advertisement in a local newspaper. Methods. The women were randomly allocated to progesterone cream 40 mg daily or 20 mg, twice daily, for 42 days. Main outcome measures. The concentration of progesterone in the serum was measured on days 1 and 42 before the morning dose, and at 2, 4, 6, 12 and 24 hours after the morning dose. Serum follicle stimulating hormone, oestradiol, testosterone and urinary pregnanediol-3-glucuronide were also measured on days 1 and 42.

Results:

Three subjects dropped out before using the cream and two more dropped out after the first treatment leaving a reportable sample of 19 women. There was a rise in the mean progesterone concentration at each sampling time between days 1 and 42. There was evidence of a rise in pregnanediol-3-glucuronide over the course of the study. There was no change in follicle stimulating hormone, oestradiol or testosterone. There was no difference between the two regimens. Conclusions. Transdermal progesterone (40 mg) per day for 42 days causes a small increase in serum progesterone concentration, although there is wide variation. Whether such levels are of clinical benefit remains to be seen.



Home Up Next


Please click on the required question.